Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
25,001 - 50,000 - Monthly Reach
Unique listeners across all episodes (30 days)
75,001 - 150,000 - Active Followers
Loyal subscribers who consistently listen
40,001 - 100,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 12 epsHosts
Recent guests
Recent episodes
Great Lectures; Great Presentations
May 1, 2026
27m 45s
DERM on RheumNow (April 2026)
May 1, 2026
15m 43s
Follow the Money (4.23.2026)
Apr 24, 2026
25m 58s
Prescribing Lessons (4.17.2026)
Apr 17, 2026
25m 05s
Top Four and More (4.10.2026)
Apr 10, 2026
25m 58s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 5/1/26 | Great Lectures; Great Presentations✨ | presentation skillslecturing+3 | — | — | — | presentationlectures+3 | — | 27m 45s | |
| 5/1/26 |  DERM on RheumNow (April 2026)✨ | dermatologypsoriasis+5 | — | SkyriziTremfya+2 | Asia-Pacific | dermatologyPsoriasis+6 | — | 15m 43s | |
| 4/24/26 | Follow the Money (4.23.2026)✨ | rheumatologyfinance+3 | — | — | — | rheumatologyfinance+3 | — | 25m 58s | |
| 4/17/26 | Prescribing Lessons (4.17.2026)✨ | rheumatologymedical news+3 | — | RheumNow.com | — | rheumatologymedical news+3 | — | 25m 05s | |
| 4/10/26 | Top Four and More (4.10.2026)✨ | newsjournal reports+3 | — | RheumNow.com | — | Rheumatologynews+3 | — | 25m 58s | |
| 4/3/26 | Whats New PsA? (4.3.2026)✨ | PsAFDA safety warnings+3 | — | FDAAAD+1 | — | PsAFDA+4 | — | 20m 59s | |
| 4/1/26 |  PsA GRAPPA Domains: Outcomes With a JAKi✨ | PsAGRAPPA domains+3 | Dr. SchwartzmanDr. Ruderman | — | — | PsAGRAPPA+3 | AbbVie Medical Affairs | 18m 06s | |
| 3/27/26 | Moral Distress (3.27.2026)✨ | moral distressFM in PsA+3 | — | RheumNow.comMDHAQ | — | moral distressFM in PsA+3 | — | 26m 41s | |
| 3/27/26 | DERM on RheumNow Podcast (March 2026)✨ | FDA approvalsdermatology+4 | — | Icotrokinrasecukinumab+5 | United States | FDAIcotrokinra+7 | — | 14m 40s | |
| 3/20/26 | Pitfalls in Rheumatology (3.20.2026)✨ | rheumatologyregulatory actions+3 | — | RheumNow.com | — | rheumatologyregulatory actions+3 | — | 26m 37s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 3/20/26 |  STEP Talks from RNL26 Part #2✨ | ObesityInflammation+3 | Dr. Uzma HaqueDr. Susan Goodman | Rheumatology | — | obesityinflammation+4 | — | 56m 57s | |
| 3/20/26 | STEP Talks from RNL26 Part #1✨ | Disease ModificationOsteoarthritis+3 | Dr. Tuhina NeogiDr. Robert Terkeltaub | — | — | OsteoarthritisGout+3 | — | 42m 25s | |
| 3/20/26 | Rheumatoid Arthritis Faculty Panel Q&A | Rheumatoid Arthritis Faculty Panel Q&A | 32m 20s | ||||||
| 3/20/26 | ILD in RA - Recent Advances. Dr. Jeffrey Sparks | ILD in RA - Recent Advances. Dr. Jeffrey Sparks | 30m 36s | ||||||
| 3/20/26 | The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle | The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle | 31m 52s | ||||||
| 3/20/26 | Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova | Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova | 30m 54s | ||||||
| 3/13/26 |  Poets Know It (3.13.2026) | Dr. Jack Cush reviews the news, regulatory decisions and new journal articles. | 25m 59s | ||||||
| 3/6/26 | UBER Rheumatology Ride (3.6.2026) | Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com | 31m 03s | ||||||
| 3/2/26 | Early Decisions and Impact: Risankizumab in Bio-Naive Patients With PsA Sponsored by AbbVie Medical Affairs + Health Impact | No description provided. | 13m 35s | ||||||
| 2/28/26 | DERM on RheumNow PODCAST (February 2026) | The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTESFDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj Review of Calcinosis Cutis - Surgical intervent. most effective (excision, curettage, laser ablation, etc). Medical measures inconsistently, partially effective, best if used early & localized (CCB, TCN, probenecid, immunomodulation, biologics, colchicine, NA thiosulfate, & JAKi https://t.co/rv0hQBv6nX Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://buff.ly/vHOSRws Dermatomyositis outcomes w/ 2475 pts (claims) & 1196 pts (EHR). Half had myositis panels & 35% had + MSAbs. Steroid use common in 69% & 74%. HCQ, MTX, MMF. Outocmes (per 1000PYs) wereL all-cause hospitalisation 92, malignancy 15.3, ILD 6.4, and myocarditis 2.1 https://t.co/DJqKGNGX76Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27) https://t.co/1REWmod73W Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM | 12m 25s | ||||||
| 2/27/26 | SATISFACTION (2.27.2026) | Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com | 24m 57s | ||||||
| 2/20/26 | Referral Rules to Live By (2.20.2026) | Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy. | 20m 15s | ||||||
| 2/14/26 | Maui Potpourri (2.13.2026) | Dr.Jack Cush reviews the hot item takeaways from last weeks RheumNow.Live 2026Diet & Obesity Management in Rheumatology - Uzma Haque, MDMitigating risk for Rheum patients undergoing orthopedic surgery - Susan Goodman, MDParadoxical skin reactions – Dr. Joseph MerolaMortality in RA - Elena Myasoedova, MDThe Mucosal Hypothesis to RA - Kristin Demourelle, MDAdvances in ILD - Jeffrey Sparks, MDSeronegative vs. Seropositive RA - Jack Cush, MD | 29m 49s | ||||||
| 2/6/26 | ANA Pollution (2.06.2026) | Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com | 25m 58s | ||||||
| 2/2/26 | DERM on RheumNow PODCAST (January 2026) | The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTESLupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa PAPA Syndrome: When Sterile Inflammation Mimics Infection (Pyogenic Arthritis, Pyoderma gangrenosum, Acne) •A rare monogenic autoinflammatory disease •Caused by gain-of-function mutations in PSTPIP1 🧠 Pathophysiology •Mutant PSTPIP1 - increased interaction with pyrin https://t.co/tJ4INdgfky Turkish study of 128 Psoriatics (62 PSO, 66 PsA) found more periodontitis in PsA vs PSO (47% vs 31%; P=.058). Assoc. w/ Signif. higher levels of Dz activity seen for PSO (CPDAI: OR 1.38; P = .001) & enthesitis (MASES: OR 1.39; P .001) if periodontitis present in PsA patients. https://t.co/d8OfarFWeG Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/EzaqS5q096 Did you know theres a Subcutaneous (SC) rituximab (Hycela)? Its same RTX but combined w/ hyaluronidase, faster 5-7 minute injection Vs hours for IV RTX. FDA approved 2017 for Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). Give 1st dose IV, then use SC RTX. https://t.co/piQ2ZhAOyf German psoriasis registry PsoBest reports on 595 Rx w/ apremilast (417 APR monotherapy). Compared to Ptx Rx w/ other DMARDs/biologic drugs, APR pts higher age, more comorbidities. Nonserious AEs: ineffectiveness (14%), diarrhea (9%), nausea (7%), HA (6%). https://t.co/TviJmM7Fr9 https://t.co/tY89oHgUgV DMARD Responses in Localized Scleroderma – MMF = MTX ~114 pts Advanced Practitioner Biologic Prescriptions for Psoriasis Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA https://t.co/3NtntmpSPV GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w | 16m 00s | ||||||
Showing 25 of 876
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
7 placements across 7 markets.
Chart Positions
7 placements across 7 markets.